entertainment -WSS

entertainment

author：hotspot 2025-09-02 11:46:57 - browse：172

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

hotspot

leisure time

WSS

Melinda French Gates resigns from Gates Foundation

Guardant Health colon cancer test endorsed by FDA advisory panel

Why does health care cost so much? A reading guide

Louisiana bill approved classifying abortion pills as controlled substances

Cancer researcher Catriona Jamieson is sending tumors into space

Getting Alzheimer's drug Leqembi to patients can be a challenge

knowledge

entertainment

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Diversity in clinical trials starts with building trust, experts say

Duchenne breakthrough therapy leaves behind pioneering families

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Diversity in clinical trials starts with building trust, experts say

Trump demands the U.S. pay no more for drugs than other countries … again

Decentralized clinical trials need collaboration to achieve wider use

Wikipedia

Element Biosciences CEO lays out genome sequencing strategy

Orangutan used medicinal plant to treat wound, first time ever seen

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

After traumatic brain injury, life support decisions can use more time

Medical students need to learn the potent medicine of empathy

Melinda French Gates resigns from Gates Foundation

hotspot

leisure time

hotspot

explore